SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request</u>. All other information may be filled in by office staff; fax to <u>1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization may be delayed.</u>

<u>Drug Requested:</u> Brexafemme[®] (ibrexafungerp)

MEMBER & P	RESCRIBER INFORMATION: Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	Date of Birth:
Prescriber Name:	
Prescriber Signatur	e: Date:
Office Contact Nan	e:
Phone Number:	Fax Number:
DEA OR NPI #: _	
DRUG INFOR	IATION: Authorization may be delayed if incomplete.
Drug Form/Strengt	h:
	Length of Therapy:
Diagnosis:	ICD Code:
Weight:	Date:
	TERIA: Check below all that apply. All criteria must be met for approval. To ecked, all documentation, including lab results, diagnostics, and/or chart notes, must be may be denied.
Diagnosis: Vul	ovaginal Candidiasis (VVC), acute infection
Recommended Do	sing: 300 mg every 12 hours for 1 day (2 doses)
Length of Auth	orization: Date of Service, one-time fill
☐ Member is po	st-menarchal
□ Provider has	confirmed that the member is not pregnant
include labo	current diagnosis for acute, uncomplicated vulvovaginal candidiasis (VVC) (please ratory documentation or medical chart notes to confirm diagnosis i.e., urinalysis, examination via 10% KOH)

(Continued on next page)

Trial and failure of oral fluconazole at the recommended dosage of 150 mg as a single dose for the treatment of VVC (pharmacy claims history and chart notes must confirm failure)	
Trial and failure of two topical agents (suppository inserts/ovules/creams) for the treatment of VV (pharmacy claims history and chart notes must confirm failure)	
☐ Gynazole-1 vaginal cream 2 %	
☐ Terconazole vaginal cream 0.4 %, 0.8 %	
☐ Terconazole vaginal suppository 80 mg	
□ OTC products: tioconazole ointment 6.5%, miconazole suppository 100 mg/200 mg, clotrimazole cream 1%, 2% /100 mg suppository	

Diagnosis: Recurring Vulvovaginal Candidiasis (RVVC)

Recommended Dosing: 300 mg every 12 hours for 1 (2 doses); repeat monthly for a total of 6 months

Length of Authorization: 6 months

- □ Provider has confirmed that the member is not pregnant
- ☐ Member is currently experiencing signs and symptoms consistent with an acute episode of VVC (e.g., vulvovaginal pain, pruritis or irritation, abnormal vaginal discharge), AND it is a laboratory confirmed VVC episode (please include laboratory documentation or medical chart notes to confirm diagnosis i.e., urinalysis, microscopic examination via 10% KOH, culture)
- \Box Member has a history of recurring VVC (RVVC) (please include past medical history notes recording RVVC, defined as ≥ 3 episodes of vulvovaginal candidiasis (VVC) in a 12-month period)
- ☐ Member remains symptomatic and culture positive after therapy with fluconazole, completing a 6-month dosing regimen as follows unless intolerant or contraindicated (please include medical chart/progress notes and laboratory results; pharmacy claims history and chart notes must confirm failure, intolerance or contraindication to therapy):
 - □ 100, 150 or 200 mg oral dose of fluconazole every third day for a total of 3 doses (days 1, 4 and 7)
 - □ Followed by oral fluconazole (100, 150 or 200 mg oral dose) weekly for 6 months as the maintenance regimen

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.